| 40.17 0 (0%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 50.42 | 1-year : | 52.81 |
| Resists | First : | 43.17 | Second : | 45.22 |
| Pivot price | 42.07  |
|||
| Supports | First : | 39.86 | Second : | 33.17 |
| MAs | MA(5) : | 40.16 | MA(20) : | 42.08 |
| MA(100) : | 37.7 |
MA(250) : | 33.54 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.6 | D(3) : | 5.6 |
| RSI | RSI(14): 34.3 | |||
| 52-week | High : | 45.22 | Low : | 22.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ XOMA ] has closed above bottom band by 24.9%. Bollinger Bands are 70.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 40.26 - 40.46 | 40.46 - 40.62 |
| Low: | 39.61 - 39.88 | 39.88 - 40.11 |
| Close: | 39.79 - 40.2 | 40.2 - 40.54 |
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.
Mon, 17 Aug 2026
XOMA Royalty Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Mon, 27 Jul 2026
A Merger Closing Mystery - Bloomberg.com
Fri, 12 Jun 2026
XOMA Royalty expects HoldCo acquisition to close ~July 14; redeems preferred stock - TradingView
Mon, 25 May 2026
Saying Goodbye To The XOMA Royalty PFDs (NASDAQ:XOMAO) - Seeking Alpha
Wed, 13 May 2026
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (NASDAQ:XOMAO) Surges as a Top Growth Stock Candidate Under Navellier's Little Book Strategy - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 18 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 85.3 (%) |
| Shares Short | 915 (K) |
| Shares Short P.Month | 852 (K) |
| EPS | 1.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.78 |
| Profit Margin | 69.6 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 1.2 % |
| Return on Equity (ttm) | 34.2 % |
| Qtrly Rev. Growth | -22.7 % |
| Gross Profit (p.s.) | 2.72 |
| Sales Per Share | 2.74 |
| EBITDA (p.s.) | 0.46 |
| Qtrly Earnings Growth | 207.8 % |
| Operating Cash Flow | 7 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | 25.58 |
| PEG Ratio | 0 |
| Price to Book value | 5.15 |
| Price to Sales | 14.62 |
| Price to Cash Flow | 104.59 |
| Dividend | 0.54 |
| Forward Dividend | 0 |
| Dividend Yield | 1.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|